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vs. 39% cirrhotic patients vs. non-cirrhotic controls). In cirrhotic
patients, the probability to ﬁnd neurocognitive alterations
increased from patients without infection (42%) to patients with
infection and no systemic inﬂammatory response syndrome
(SIRS) (79%) to those with sepsis (90%). Efﬁcaciously treated
patients, in whom the infection subsided, improved their neuro-
logical symptoms. Both overt and covert hepatic encephalopathy
were inﬂuenced by the presence of infection and by its
resolution.
These results are in keeping with a role for inﬂammation in
the pathogenesis of HE [4]. Other authors have supported this
hypothesis: the administration of LPS has been found to alter
consciousness and to exacerbate brain oedema only in rats with
liver damage [5]; and ibuprofen restored the learning ability of
rats with portacaval shunts and cognitive impairment [6]. In
cirrhotic patients, serum levels of TNF-alfa [7], as well as of IL-6
and IL-18 [8,9] were associated with the presence and severity
of overt and minimal HE. Indeed pro-inﬂammatory cytokines
may contribute to HE in cirrhotic patients by acting synergically
with hyperammonemia [10]. Interestingly, in our study [3] the
mean ammonia plasma levels associated with OHE were lower
in patients with concomitant infection/inﬂammation than in
those without infection.
Letters to the EditorTo the Editor:
We read with interest ‘‘The Hepatic Encephalopathy Practice
Guidelines’’ published in the September issue of the Journal of
Hepatology [1].
As underlined by the authors in Table 3, infections are
extremely frequent as precipitating factors for overt hepatic
encephalopathy (OHE). In our tertiary referral centre, with
an ongoing project for the search of active infection at
hospital admission, infection was the precipitating event
in 56% of patients with OHE in a study performed in
2008 and 2009 [2]. This prevalence has increased to 64%
in 2012 (personal data).
In the same article however, the authors claim that ‘‘patients
with cirrhosis do not differ from patients without cirrhosis
regarding their risk to develop brain dysfunction with sepsis’’.
We disagree with this information. We have recently investigated
the association between bacterial infections and cognitive
dysfunction in 150 cirrhotic patients and 81 non-cirrhotic con-
trols [3]. Signs of neurocognitive impairment were systematically
looked for by means of standardized clinical examination or by
the application of psychometric tests in both groups. Following
a diagnosis of sepsis, neurocognitive alterations were signiﬁ-
cantly more frequent in cirrhotic patients than in controls (90%746 Journal of Hepatology 2015 vol. 62 j 739–752
Open access under CC BY-NC-ND license.
We would like to emphasize the importance of actively
searching for infections, even if not clinically evident, in any
cirrhotic patient with cognitive impairment.
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Partial hepatectomy vs. transcatheter arterial chemoembolization
for resectable multiple hepatocellular carcinoma beyond
Milan criteria: A RCT
To the Editor:
Yin and colleagues are to be congratulated on having performed
an RCT in such a challenging study population [1]. The results are
strongly supportive of surgery in preference to transarterial
chemoembolization (TACE), in patients beyond Milan criteria at
BCLC B. But, the ﬁndings must be viewed with caution before a
similar approach is pursued in different patient populations.
Firstly, the disease aetiology was almost exclusively due to
chronic hepatitis B infection. A recent UK study showed that
70% of cases of HCC were due to alcoholic liver disease, fatty liver
disease, and cryptogenic disease, so the patient groups between
geographical locations are clearly very different and thus not
comparable. Furthermore, the mean age in the far eastern popu-
lation was 52 and 54 years for the partial hepatectomy patients
and TACE patients, respectively. This compares with a median
age of 69.9 years in the study from the Newcastle group [2].
Excluding patients 70 years or older is likely to have introduced
a selection bias to the study, since older patients are more likely
to have signiﬁcant co-morbidities that would preclude major
liver resection. The normal platelet counts may also hint at low
levels of signiﬁcant portal hypertension, which is known to be
associated with poorer outcomes following partial hepatectomy.
Moreover, 22% of the surgical patients and 13% of the TACE
patients were not cirrhotic, but for those patients who were
cirrhotic, more Child-Pugh B patients were in the TACE group
(although this approached, but did not reach statistical signiﬁ-
cance). Finally, the authors highlight the poorer than anticipated
outcomes from TACE and the lack of access to drug eluted beads
[3–6]. The lack of access to these treatments is understandable,
but the questions remain: ‘‘Would the outcomes have been dif-
ferent had this been available’’? In summary, the fact that Yin
and colleagues were able to perform and complete this study is
a major achievement, but due to the understandable difﬁculties
in the methodology, it would be too early to suggest that BCLC
B patients outside Milan should be offered surgery before TACE.
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